2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Btk

Btk

Bruton tyrosine kinase

Btk

Related Products

PDF 1.37 MB

Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152212
    BTK-IN-19
    		Inhibitor
    BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM.
    BTK-IN-19
  • HY-151211
    BTK-IN-16
    		Inhibitor 98.93%
    BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.
    BTK-IN-16
  • HY-153536
    PROTAC BTK Degrader-3
    		Inhibitor
    PROTAC BTK Degrader-3 is a potent BTK degrader with a DC50 value of 10.9 nM of BTK degradation in Mino cells. PROTAC BTK Degrader-3 has the potential for B-cell malignancies, including chronic lymphoid malignancies research.
    PROTAC BTK Degrader-3
  • HY-E70808
    BTK C481R Recombinant Human Active Protein Kinase
    Bruton's tyrosine kinase (BTK) plays a vital role in B-cell antigen receptor (BCR) signalling transduction pathway. BTK can be used for the study of lymphomas and autoimmune diseases. BTK has multiple mutants. BTK C481R Recombinant Human Active Protein Kinase is a recombinant BTK C481R protein that can be used to study BTK C481R-related functions.
    BTK C481R Recombinant Human Active Protein Kinase
  • HY-181624
    BTK ligand-19
    		Ligand
    BTK ligand-19 is a PROTAC ligand of BTK, which is used to synthesize the PROTAC-based BTK degrader PROTAC BTK degrader-14 (HY-181623). BTK ligand-19 regulates cell apoptosis, cell cycle progression and kinase signaling cascades. BTK ligand-19 is applied in cancer research.
    BTK ligand-19
  • HY-141689
    BTK-IN-3
    		Inhibitor
    BTK-IN-3 (example 1) is an inhibitor of BTK. BTK-IN-3 can used to study cancer.
    BTK-IN-3
  • HY-162280
    PROTAC BTK Degrader-9
    		Degrader
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model.
    PROTAC BTK Degrader-9
  • HY-168302
    BTK ligand 10
    BTK ligand 10 is the ligand of BTK. BTK ligand 10 can be used to synthesize NX-2127 (HY-153220).
    BTK ligand 10
  • HY-168963
    PROTAC BTK Degrader-13
    		Degrader
    PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC50 of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC50 of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway. (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))
    PROTAC BTK Degrader-13
  • HY-124605
    IQS-019
    		Inhibitor
    IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma.
    IQS-019
  • HY-E70809
    BTK V416L Recombinant Human Active Protein Kinase
    Bruton's tyrosine kinase (BTK) plays a vital role in B-cell antigen receptor (BCR) signalling transduction pathway. BTK can be used for the study of lymphomas and autoimmune diseases. BTK has multiple mutants. BTK V416L Recombinant Human Active Protein Kinase is a recombinant BTK V416L protein that can be used to study BTK V416L-related functions.
    BTK V416L Recombinant Human Active Protein Kinase
  • HY-143716
    JAK3/BTK-IN-1
    		Inhibitor
    JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
    JAK3/BTK-IN-1
  • HY-100335R
    PCI-33380 (Standard)
    		Inhibitor
    PCI-33380 (Standard) is the analytical standard of PCI-33380 (HY-100335). This product is intended for research and analytical applications. PCI-33380 is a fluorescent probe ( (Ex=532 nm, Em=555 nm). PCI-33380 consists of a (BTK) inhibitor PCI-32765 (HY-10997) attaching with a Bodipy-FL fluorophore via a piperazine linker. PCI-33380 binds predominantly to Btk in B cell lysates with cell permeable activity. PCI-33380 can be used for imaging live cancer cells such as non-Hodgkin lymphoma research
    PCI-33380 (Standard)
  • HY-101793R
    BMS-935177 (Standard)
    		Inhibitor
    BMS-935177 (Standard) is the analytical standard of BMS-935177 (HY-101793). This product is intended for research and analytical applications. BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM.
    BMS-935177 (Standard)
  • HY-109010R
    Poseltinib (Standard)
    		Inhibitor
    Poseltinib (Standard) is the analytical standard of Poseltinib (HY-109010). This product is intended for research and analytical applications. Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine Kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis.
    Poseltinib (Standard)
  • HY-101474R
    (±)-Zanubrutinib (Standard)
    		Inhibitor
    (±)-Zanubrutinib (Standard) is the analytical standard of (±)-Zanubrutinib (HY-101474). This product is intended for research and analytical applications. (±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC50 of 0.63 nM.
    (±)-Zanubrutinib (Standard)
  • HY-13036C
    (Rac)-IBT6A hydrochloride
    		Inhibitor
    (Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
    (Rac)-IBT6A hydrochloride
  • HY-101941R
    BTK IN-1 (Standard)
    		Inhibitor
    BTK IN-1 (Standard) is the analytical standard of BTK IN-1 (HY-101941). This product is intended for research and analytical applications. BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM.
    BTK IN-1 (Standard)
  • HY-181623
    PROTAC BTK degrader-14
    		Degrader
    PROTAC BTK degrader-14 (compound 112) is a PROTAC protein degrader targeting BTK. PROTAC BTK degrader-14 can be used for the research of cancer.
    PROTAC BTK degrader-14
  • HY-168292
    BTK ligand 9
    BTK ligand 9 is a target protein ligand for BTK and can be used to synthesize PROTAC DD-03-171 (HY-122830).
    BTK ligand 9
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity